Work

Sensorineural Hearing Loss after Chemoradiotherapy with High-Dose Cisplatin in Patients with Head and Neck Cancer

Year: 2025

Type: article

Abstract: Objective To investigate sensorineural hearing loss in patients with head and neck cancer receiving chemoradiotherapy (CRT) with a standard regimen of high-dose cisplatin, focusing on the acute changes before and after CRT with high-dose cisplatin (CDDP). Materials and Methods A total of, 135 cases of head and neck cancer treated with high-dose cisplatin-based CRT between 2014 and 2023 were included in this retrospective study. The hearing threshold shifts at each frequency before and after each CDDP dose were used as an indicator to assess hearing impairment. Results The CRT-induced hearing threshold shift was greater at frequencies >4,000 Hz, with a threshold increment of ∼10 dB at 4,000 Hz and 20 dB at 8,000 Hz. The threshold after each course of CDDP was elevated at one week after CDDP administration, and the changes in the thresholds from one week after administration to just before the subsequent course were small. Total CDDP dose, radiation dose to the cochlea, and mean pretreatment hearing thresholds were identified as significant factors influencing the increase in hearing thresholds at 8,000 Hz. Conclusion In patients with head and neck cancer receiving CRT with high-dose cisplatin, threshold increment was predominantly observed at frequencies >4,000 Hz, as previously reported. The threshold increment occurred immediately after CDDP administration, which might be relevant when considering the timing of future interventions.

Source: International Journal of Practical Otolaryngology

DOI: 10.1055/s-0045-1802338